Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients with Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease

Inclusion Criteria

• Ability to understand and the willingness to sign a written informed consent document
• Patients must be scheduled for a procedure capable of providing a definitive pathologic diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either upper endoscopy or surgical esophagectomy
• One of the following inclusion criteria must be true for patient to be eligible for enrollment:
• Subjects with known esophageal cancer (adenocarcinoma or squamous cell carcinoma)
• Subjects with a history of low or high grade dysplasia
• Subjects with risk factors for esophageal malignancy including Barrett’s esophagus and gastroesophageal reflux disease (GERD)

Exclusion Criteria

• Subjects that are unable to swallow a tablet/pill
• Subjects with completely obstructing esophageal cancer
• Subjects with known or suspected esophageal varices
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Any condition which, in the opinion of the investigator precludes the patient from completion of the study procedure